Priti Patel - 31 Mar 2023 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
Former Chief Medical Officer
Signature
/s/ Sean Smith, as Attorney-in-Fact for Priti Patel
Issuer symbol
NLTX
Transactions as of
31 Mar 2023
Net transactions value
-$2,608
Form type
4
Filing time
04 Apr 2023, 20:51:03 UTC
Previous filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NLTX Common Stock Options Exercise $0 +10,000 +32% $0.000000 41,082 31 Mar 2023 Direct
transaction NLTX Common Stock Sale $2,608 -3,769 -9.2% $0.6919 37,313 03 Apr 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Restricted Stock Units Options Exercise $0 -10,000 -100% $0.000000* 0 31 Mar 2023 Common Stock 10,000 $0.000000 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Priti Patel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F4 The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer.
F5 The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.